PMV Pharmaceuticals (PMVP) AI Stock Analysis

• Market Cap: $77.33M
• Dividend Yield: N/A
• Average Volume (3M): 881.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: -58.47%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 53,329,390
• 10 Day Avg. Volume: 410,574
• 30 Day Avg. Volume: 881,551
• PEG Ratio: -0.03
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.89
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -414.25
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.37
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $1.50 ▲(33.93% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is held back primarily by weak financial performance (no revenue, persistent and worsening losses, and increasing cash burn) despite low leverage. Technicals are a near-term positive with the stock above key moving averages and supportive momentum indicators. Valuation remains constrained by negative earnings and no dividend support.

Positive Factors

Low Leverage

Very low debt reduces risk of near-term financing stress and interest obligations, preserving operational flexibility. For a clinical-stage biotech this durable low-leverage profile supports pursuing trials or partnerships without immediate default risk, improving negotiating power for deals.

Focused Precision Oncology Pipeline

A clear, biomarker-driven focus on p53-targeted small molecules creates a durable competitive niche. Precision targeting of genetically defined cancer drivers can enable efficient trial design, clearer patient selection, and stronger partnership or acquisition interest if clinical signals emerge.

Partnership Funding Pathways

As a pre-revenue biotech, access to collaboration, milestone and royalty structures is a structural funding lever that can provide non-dilutive or milestone-tied capital. This pathway can extend runway and de-risk programs versus sole reliance on equity issuances over the medium term.

Negative Factors

Persistent Pre-revenue Losses

The company remains pre-revenue with recurring operating losses, meaning no product income to offset R&D spend. This structural lack of revenue increases dependence on external financing and partnerships, and keeps profitability distant until successful commercialization or sustained licensing.

Rising Cash Burn

Operating cash burn increased materially in 2025 versus 2024, and operating/free cash flow have been negative every year shown. Higher sustained burn raises the probability of further financings, which can dilute shareholders and constrain long-term R&D planning absent new revenue or partnership inflows.

Eroding Equity Base

Steady erosion of shareholder equity reflects cumulative losses and reduces the balance-sheet buffer against setbacks. Even with low debt, a shrinking equity base limits flexibility for large strategic moves and increases vulnerability if financing windows tighten or clinical setbacks require expensive pivots.

PMV Pharmaceuticals Business Overview & Revenue Model

Company Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

How the Company Makes Money

As a clinical-stage biotechnology company, PMV Pharmaceuticals has historically generated little to no recurring revenue from product sales because its programs have been in research and clinical development rather than commercial distribution. To the extent the company generates revenue, it is typically from collaboration- and partnership-related payments (e.g., upfront payments, research funding reimbursements, and potential development, regulatory, and commercial milestone payments) and, if applicable, royalties tied to partnered product sales. If there are no active collaborations producing recognized revenue in a given period, the company’s reported revenue may be null or minimal, and it primarily funds operations through financing activities such as issuing equity or other capital-raising transactions rather than operating income.

PMV Pharmaceuticals Financial Statement Overview

Summary

Pre-revenue with persistent operating losses and worsening net loss in 2025 versus 2024. Cash flow remains consistently negative with higher cash burn in 2025, increasing future financing needs. Offsetting this somewhat is very low leverage, which reduces balance-sheet financial risk despite a materially declining equity base.

Income Statement

Across 2020–2025 annual periods, the company reports no revenue and consistent operating losses (EBIT and EBITDA negative every year). Net losses remain sizable and in 2025 worsened versus 2024 (net loss of ~$77.7M vs. ~$58.7M), indicating profitability is not yet trending toward breakeven. A modest positive is that losses have not been strictly linear year-to-year, but overall the earnings profile remains heavily loss-making with no revenue base to absorb operating spend.

Balance Sheet

Leverage is very low, with total debt minimal relative to equity (debt-to-equity generally near zero and improving sharply in 2024–2025). However, the equity base has been declining materially over time (from ~$359M in 2020 to ~$105M in 2025), reflecting ongoing losses and balance sheet consumption. Returns on equity are consistently negative and deteriorated in 2025, which highlights that while the company is not debt-stressed, it is steadily using up capital.

Cash Flow

Cash generation remains weak: operating cash flow and free cash flow are negative in every year shown, consistent with a pre-revenue biotech cash-burn model. Cash burn increased in 2025 versus 2024 (operating cash flow about -$73.6M vs. -$51.3M), signaling higher spend or reduced working-capital support. A relative positive is that free cash flow closely tracks net loss (cash burn broadly in line with accounting losses), but the direction in 2025 indicates rising funding needs unless spending moderates or revenue sources emerge.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-133.00K	-1.14M	-1.26M	-650.00K	-1.28M
EBITDA	-86.21M	-73.67M	-67.70M	-72.68M	-56.54M
Net Income	-77.74M	-58.71M	-68.96M	-73.32M	-57.85M
Balance Sheet
Total Assets	116.56M	191.29M	252.15M	270.31M	331.57M
Cash, Cash Equivalents and Short-Term Investments	112.94M	169.45M	203.06M	241.05M	297.16M
Total Debt	838.00K	1.19M	13.29M	13.98M	11.19M
Total Liabilities	11.85M	15.21M	26.46M	24.28M	23.01M
Stockholders Equity	104.71M	176.08M	225.69M	246.03M	308.56M
Cash Flow
Free Cash Flow	-73.61M	-51.94M	-56.62M	-71.74M	-47.92M
Operating Cash Flow	-73.58M	-51.28M	-55.66M	-63.76M	-46.57M
Investing Cash Flow	70.17M	53.35M	-50.55M	-1.37M	-143.58M
Financing Cash Flow	505.00K	313.00K	35.58M	958.00K	2.02M

PMV Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Neutral. The current price of 1.12 is below the 20-day moving average (MA) of 1.52, below the 50-day MA of 1.27, and below the 200-day MA of 1.31, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.53 is Neutral, neither overbought nor oversold. The STOCH value of 6.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PMVP.

PMV Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRLD	60 Neutral	$199.09M	-2.24	-129.98%	―	250.00%	15.15%
PMVP	53 Neutral	$77.33M	-0.84	-59.07%	―	―	-58.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XFOR	48 Neutral	$370.04M	―	-115.27%	―	2925.73%	-294.29%
GANX	46 Neutral	$72.69M	-2.93	-341.33%	―	―	42.29%
ABVC	41 Neutral	$31.29M	-6.26	-88.89%	―	56.52%	75.22%